Hunterase extended trial shows promise for managing hunter syndrome
NCT ID NCT07344376
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the long-term safety and effectiveness of Hunterase (idursulfase beta) in 30 people with Hunter syndrome over about one year. Participants had either completed a previous phase 3 study or had used Hunterase for at least six months. The goal was to monitor side effects and track changes in walking ability and urine markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hunterase (idursulfase beta)
- What this could lead to
- If successful, this could confirm that long-term use of Hunterase is safe and helps manage symptoms of Hunter syndrome.
- What could go wrong
- This is an extension study with only 30 participants, so results may not apply to everyone. It focuses on safety, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GC1111 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lifeline for hunter syndrome patients: continued access to Brain-Targeting therapy
- Early enzyme therapy may help kids with rare disease grow better
- Home infusions may help patients stick to treatment
- Groundbreaking trial aims to treat rare diseases in the womb
- Major study tracks rare brain diseases to unlock their secrets
- New stem cell approach aims to tame rare genetic diseases